智通财经APP讯,盟科药业(688373.SH)公告,公司近日收到国家药品监督管理局签发的关于MRX-5片用于治疗对本品敏感的非结核分枝杆菌引起的感染的《药物临床试验批准通知书》。公告显示,MRX-5是一种新型苯并硼唑类抗生素,拟用于治疗分枝杆菌属,特别是由NTM引起的感染。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.